Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Eisai Announces China Approval for Liver Cancer Treatment

publication date: Sep 5, 2018

Eisai and Merck/MSD announced the China National Medical Products Administration (NMPA) approved Lenvima^® (lenvatinib) as a first-line treatment for unresectable hepatocellular carcinoma. It is the first China approval for Lenvima, where the incidence of HCC is high, and the first new systemic therapy approved in China for first-line treatment of unresectable HCC in ten years. The NMPA completed its review in 10 months under Priority Review procedures. More details....

Stock Symbols: (TYO: 4523) (NYSE: MRK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.